Boston Scientific Corporation
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Boston Scientific Corporation sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Boston Scientific Corporation: 280 sponsored US clinical trials, 22 recruiting.
Boston Scientific Corporation sponsors 280 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 207 completed. 59 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 8 trials.
Top-decile sponsor footprint
Boston Scientific Corporation ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
207 of 239 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 6 of 6
A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions
NCT00371475
A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels
NCT00371748
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
NCT00129545
MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy
NCT00180271
Spinal Cord Stimulation for Low Back Pain
NCT00205868
PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy
NCT00146848
SITELINE 2 Polyurethane
NCT00180284
Safety and Efficacy of CryoCor™ Cryoablation for PAF
NCT00231296
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
NCT00569751
The EASYTRAK EPI Clinical Investigation
NCT00158925
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
NCT00371709
Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence
NCT00688298
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
NCT00131573
TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program
NCT00569491
Occipital Nerve Stimulation to Treat Chronic Headaches
NCT00205894
A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.
NCT00597142
Contak Renewal 3 AVT
NCT00158977
An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
NCT00080470
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis
NCT00287573
ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations
NCT00231426
Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF
NCT00158951
An Implantable Spinal Cord Stimulation Pain Management System
NCT00205855
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
NCT00301522
A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
NCT00646048
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
NCT00292474
Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts
NCT00283413
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
NCT00316108
Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™
NCT00600327
Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure
NCT00180258
Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
NCT00387803
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 16 |
| Phase 3 | 33 |
| Phase 4 | 26 |
Therapeutic Areas
Where Boston Scientific Corporation enrollment is open (later-stage tilt)
22 recruiting of 280 indexed (8% open); 207 completed (74%).
Phase mix: 59 late (III/IV) vs 23 early (I/II) (later-stage heavy).
Top condition: Coronary Artery Disease (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Boston Scientific Corporation: open-pipeline peers nationwide
Peers matched on 280 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Regeneron Pharmaceuticals · 280 trials · 22% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Novo Nordisk A/S · 8% recruiting · 431 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
- United Therapeutics · 8% recruiting · 63 trials
Related
What to do with this Boston Scientific Corporation page
280 registered trials is a research-attention snapshot, not an endorsement of Boston Scientific Corporation or any single study.
- 22 of Boston Scientific Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition Boston Scientific Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Boston Scientific Corporation pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.